APN.JO
APN.JO
ZAE000066692
Aspen Pharmacare Hldgs Ltd
Loading chart...

Company Profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Sandostatin, Sustanon, and Xylocaine brands. It also provides over-the-counter topical products through retail pharmacy and fast-moving consumer goods sectors under the EMLA, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for therapeutic areas, including anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Meticorten brands. In addition, the company manufactures active pharmaceutical ingredients; finished dose form products manufactured for third parties; and heparin-based API to third parties. Further, it exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Related stocks

4015.SR
4015.SR • Saudi Arabia
Jamjoom Pharmaceuticals Factory
128 SAR
2.39B USD 1Y -19.2%
2230.SR
2230.SR • Saudi Arabia
Saudi Chemical Co.
7.22 SAR
1.62B USD 1Y +0.6%
2070.SR
2070.SR • Saudi Arabia
Saudi Pharmaceutical Industries
30.46 SAR
968.19M USD 1Y +2.8%
ECILC.IS
ECILC.IS • Türkiye
ECZACIBASI ILAC
62.3 TRY
866.66M USD 1Y -32%
4016.SR
4016.SR • Saudi Arabia
Middle East Pharmaceutical Indu
63.25 SAR
589.55M USD 1Y -17.4%
128940.KS
128940.KS • South Korea
HanmiPharm
480,500 KRW
4.55B USD 1Y +35.5%
600329.SS
600329.SS • China
TIANJIN PHARMACEUTICAL DA REN T
35.8 CNY
4.13B USD 1Y -17.6%
RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
36.7% p.a.
Max Drawdown (5Y)
-63.9%
Sharpe Ratio (5Y)
-0.28
Beta Factor
0.52
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 1173.8 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -79.9% in the extended horizon.
ende